NCT06003114View on ClinicalTrials.gov

A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

CompletedOBSERVATIONAL
Enrollment

472

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions
Breast Cancer
Interventions
DRUG

Palbociclib

Participants taking oral palbociclib as prescribed in first-line treatment.

Trial Locations (1)

T5J 3E4

Alberta Health Services, Edmonton

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06003114 - A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs | Biotech Hunter | Biotech Hunter